- Home
- SNYR vs SABS Comparison
SNYR vs SABS Comparison
Compare SNYR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNYR
- SABS
- Stock Information
- Founded
- SNYR 2010
- SABS 2014
- Country
- SNYR United States
- SABS United States
- Employees
- SNYR N/A
- SABS N/A
- Industry
- SNYR
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SNYR
- SABS Health Care
- Exchange
- SNYR NYSE
- SABS Nasdaq
- Market Cap
- SNYR 16.6M
- SABS 15.8M
- IPO Year
- SNYR N/A
- SABS N/A
- Fundamental
- Price
- SNYR $2.07
- SABS $1.86
- Analyst Decision
- SNYR Strong Buy
- SABS Strong Buy
- Analyst Count
- SNYR 1
- SABS 6
- Target Price
- SNYR $10.00
- SABS $11.17
- AVG Volume (30 Days)
- SNYR 50.5K
- SABS 81.5K
- Earning Date
- SNYR 05-15-2025
- SABS 06-10-2025
- Dividend Yield
- SNYR N/A
- SABS N/A
- EPS Growth
- SNYR N/A
- SABS N/A
- EPS
- SNYR 0.30
- SABS N/A
- Revenue
- SNYR $33,592,914.00
- SABS $377,835.00
- Revenue This Year
- SNYR N/A
- SABS N/A
- Revenue Next Year
- SNYR $15.97
- SABS $50.00
- P/E Ratio
- SNYR $6.33
- SABS N/A
- Revenue Growth
- SNYR N/A
- SABS N/A
- 52 Week Low
- SNYR $0.12
- SABS $1.00
- 52 Week High
- SNYR $10.00
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- SNYR N/A
- SABS 55.20
- Support Level
- SNYR N/A
- SABS $1.73
- Resistance Level
- SNYR N/A
- SABS $2.00
- Average True Range (ATR)
- SNYR 0.00
- SABS 0.18
- MACD
- SNYR 0.00
- SABS -0.00
- Stochastic Oscillator
- SNYR 0.00
- SABS 46.07
About SNYR SYNERGY CHC CORP
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.